

Best Evidence Summaries of Topics in Mental Healthcare

BEST in MH clinical question-answering service

Question

"In adults with depression, how effective is adding psychiatric medication to psychotherapy compared with psychotherapy alone for improving patient outcomes?"

Clarification of question using PICO structure

Patients: Adults with depression-related diagnoses

Intervention: Combination of psychiatric medication and psychotherapy

Comparator: Psychotherapy alone

Outcome: Improving patient outcomes



Email: awp.BESTinMH@nhs.net Phone: 0117 378 4232/4233/4335

Clinical and research implications

No definite clinical implications can be made from the current evidence. The studies included in this BEST summary included patients with different severities of depression, and also evaluated different medications and types of psychotherapy, so that generalisations are difficult to make. One well conducted systematic review (which included studies evaluating any type of pharmacotherapy and any type of psychotherapy) reported that combined treatment was more effective than psychological treatment alone in the short-term. The authors also reported, however, that these results should be treated with caution.

None of the included studies made clear research recommendations. The authors of the systematic review stated that more long-term studies needed to evaluate the relative efficacy of psychological and combined treatments, and that more basic research is required to explore the mechanisms through which both treatments work.

What does the evidence say?

Number of included studies/reviews (number of participants)

Two systematic reviews (SRs) (Cuijpers et al. 2009; 2012), one 'mega-analysis' (de Maat et al. 2008), and two randomised controlled trials (RCTs) (Blom et al. 2007; Zu et al. 2014) met the inclusion criteria for this BEST summary.

Main Findings

A meta-analysis by Cuijpers et al. (2009) demonstrated that patients who received psychotherapy and pharmacotherapy had lower levels of depression in the short-term than patients who received psychotherapy alone (SMD 0.35 [95%CI: 0.24 to 0.45), p<0.001, but the authors suggested that these results should be treated with caution as no difference was found in the longer term, and because a number of the included studies had methodological limitations. A later review by Cuijpers et al. (2012), which included a number of the same papers as in the 2009 publication, reported meta-analyses by specific population groups/characteristics, with a view towards developing personalised treatments. Six patient 'characteristics' were defined in studies that compared combined treatment versus psychotherapy alone in depressed patients: patients with dysthymia, patients with chronic depression, older adults, stroke patients, primary care patients, and outpatients. Meta-analysis demonstrated significant results in favour of combined treatment for only two of these groups: patients with chronic depression (SMD 0.41 [95% CI: 0.35 to 0.73], p<0.001), and outpatients (SMD 0.40 [95% CI: 0.13 to 0.67], p<0.01).

One study pooled original data from three RCTs conducted in patients with mild-to-moderate major depression (de Maat et al. 2008). In their 'mega-analysis', the authors reported that independent observers and therapists did not observe a difference in symptom reduction in patients who were treated with combined therapy (pharmacotherapy and short psychodynamic supportive psychotherapy) vs. short psychodynamic supportive psychotherapy alone. For patient reported outcomes (i.e. SCL-depression and QLDS), however, combined therapy was found to be significantly more effective in treating symptoms of depression than psychotherapy alone.

An RCT by Blom et al. (2007) aimed to assess the efficacy of the combination of interpersonal psychotherapy and medication (nefazodone) with both treatment forms alone in the acute

treatment of 193 depressed outpatients. After 12-16 weeks of treatment, the authors found that all treatments were effective, but there were no significant differences between treatments on the HAMD. In contrast, the combination of medication with psychotherapy was found to be more effective in reducing depressive symptoms (as measured using MADRS) compared to medication alone, but not to psychotherapy alone.

A recent RCT examined the effects of cognitive behavioural therapy (CBT) in 180 Chinese patients with moderate to severe major depressive disorder (Zu et al. 2014). Similar to other studies, this trial included several intervention groups including antidepressants alone (citalopram, escitalopram, paroxetine or sertraline), CBT alone, combined CBT and antidepressants, or standard treatment. They authors found no significant difference between any of these treatment groups for depressive symptomology.

Authors Conclusions

Cuijpers et al. (2009) concluded that combined treatment is more effective than psychological treatment alone, although it is not clear whether this difference is relevant from a clinical perspective.

Cuijpers et al. (2012) concluded that although a considerable number of studies have compared medication, psychotherapy, and combined treatments, some preliminary results are useful for deciding which treatment is best for which patient.

de Maat et al. (2008) concluded that no difference in efficacy was found between short psychodynamic supportive psychotherapy and combined therapy, except that patients thought that combined therapy was more efficacious in terms of symptom reduction.

Blom et al. (2007) concluded that their study supports the use of combining medication with psychotherapy, over medication alone for the treatment of depressed outpatients. They also stated that, in their study, combination treatment did not have an advantage over psychotherapy alone.

Zu et al. (2014) concluded that CBT appears to be a feasible and equally effective method (compared to medication alone, or combined, or standard treatment) for treating moderate to severe depression in Chinese patients.

Reliability of conclusions/Strength of evidence

Both SRs were considered to have a low risk of bias, so that the authors' (cautious) conclusions are likely to be reliable. The meta-analysis by de Maat et al. (2008) and the RCT by Blom et al. (2007) had an unclear risk of bias so that the reliability of their results is uncertain. The Zu et al. (2014) trial was considered to have a high risk of bias. The authors appropriately noted the limitations of their trial, and also stated that their results should be viewed with caution.

What do guidelines say?

NICE guidelines (NICE, 2009) makes the following comments regarding the use of psychotherapy compared with combined psychotherapy and pharmacotherapy:

"For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT)." (pp.22)

"For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT." (pp.32)

"For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service." (pp.32)

Date question received: 18/09/2006

Date searches conducted: 18/08/2014, updated from 09/2006

Date answer completed: 08/09/2014

References

SRs

Cuijpers, P., van Straten, A., Warmerdam, L., & Andersson, G. (2009). Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. *Depression and anxiety*, 26(3), 279-288.

Cuijpers, P., Reynolds, C. F., Donker, T., Li, J., Andersson, G., & Beekman, A. (2012). Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. *Depression and anxiety*, *29*(10), 855-864.

Mega-Analyses

de Maat, S., Dekker, J., Schoevers, R., van Aalst, G., Gijsbers-van Wijk, C., Hendriksen, M., ... & de Jonghe, F. (2008). Short Psychodynamic Supportive Psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three Randomized Clinical Trials. *Depression and anxiety*, 25(7), 565-574.

RCTs

Blom, M. B., Jonker, K., Dusseldorp, E., Spinhoven, P., Hoencamp, E., Haffmans, J., & van Dyck, R. (2007). Combination treatment for acute depression is superior only when psychotherapy is added to medication. *Psychotherapy and Psychosomatics*, *76*(5), 289-297.

Zu, S., Xiang, Y. T., Liu, J., Zhang, L., Wang, G., Ma, X., ... & Li, Z. J. (2014). A comparison of cognitive-behavioral therapy, antidepressants, their combination and standard treatment for Chinese patients with moderate—severe major depressive disorders. *Journal of affective disorders*, *152*, 262-267.

Guidelines

National Institute of Health and Care Excellence. (2009). *Depression in Adults: The Treatment and Management of depression in Adults. CG90*. London: National Institute of Health and Care Excellence.

Results

Systematic Reviews

Author	Search	Inclusion criteria	Number	Summary of results	Risk of bias
(year)	Date		of		
			included		
			studies		
Cuijpers et	12/2007	Participants: Studies were included when all	19	There was a significant effect in favour of	Low
al. (2009)		randomized participants had a diagnosed	(n=1,838	combined treatment, such that patients who	
		depressive disorder, or scored above a cut-off	participa	received psychotherapy and	
		point on a self-report instrument. Comorbid	nts)	pharmacotherapy had lower levels of	
		general medical or psychiatric disorders were not		depression than patients who received	
		used as an exclusion criterion.		psychotherapy alone (SMD 0.35 [95%CI: 0.24	
		Intervention: Any psychotherapy (e.g., Cognitive		to 0.45), p<0.00l, I squared = 0.	
		Behavioural Therapy, Interpersonal			
		Psychotherapy).		None of the analyses indicated a significant	
		Comparator: Any combination of psychotherapy		difference between psychological and	
		and pharmacotherapy (e.g., antidepressants).		combined treatments at 3-6 months follow-	
		Studies were excluded if they involved		up, and at 12 months follow-up.	
		maintenance treatments or if a psychological			
		treatment plus placebo were compared to a			
		psychological treatment plus active			
		antidepressant, in case the placebo has an effect.			
0	04/0044	Outcome: Depressive symptomatology.			
Cuijpers et	01/2011	Participants: Patients from outpatient and primary	52	The authors conducted analyses for three	Low
al. (2012)		care settings with a diagnosed depressive disorder,	(n=4,734	types of comparisons (pharmacotherapy vs,	
		aged 18 years and over.	participa	psychotherapy, pharmacotherapy vs.	
		Studies were selected in which one of the	nts)	combined, and psychotherapy vs. combined)	
		comparisons (pharmacotherapy versus		– we have only extracted data on the last	

psychotherapy, pharmacotherapy versus comparison as it is relevant to this BEST combined, psychotherapy versus combined) was summary. examined in a specific target group with (a) a predefined sociodemographic characteristic (e.g., In this review, meta-analyses were older adults or minority groups), (b) with a specific conducted within specific target populations. type of depression (e.g., dysthymia, chronic Combined treatment was found to have a depression, or postnatal depression), (c) significantly better impact than depression and a comorbid (mental or somatic) psychotherapy alone for patients with disorder, or (d) a target group from a specific chronic depression (SMD 0.41 [95% CI: 0.35 setting (outpatients, primary care). Studies in to 0.73], p<0.001), but not for patients with which patients were recruited from the community were excluded because this does not dysthymia. Results were also significant for represent a specific or definable patient group outpatients (SMD 0.40 [95% CI: 0.31 to which could be included in the analysis. 0.67], p<0.01), but not for patients in Intervention: Any psychotherapy (e.g., Cognitive primary care settings. Results were non-Behavioural Therapy, Interpersonal significant between treatments in studies Psychotherapy). conducted in older adults, and in studies of Comparator: pharmacotherapy (e.g., stroke patients. No other target populations antidepressants); any combination of were evaluated for this comparison. psychotherapy and pharmacotherapy. Outcome: Depressive symptomatology (Beck Depression Inventory; HRSD).

Mega-Analyses

Author	Inclusion criteria	Number of	Summary of results	Risk of bias
(year)		participants		
De	Participants: Patients aged 18-65 years	N = 313	The authors compared pharmacotherapy alone vs.	Unclear
Maat	with a DSM-III-R or DSM-IV diagnosis of	(pharmacotherapy	psychotherapy alone, pharmacotherapy alone vs. combined	
(2008)	major depression with or without	= 45,	treatment, and psychotherapy alone vs. combined	

dysthymia, with HDRS baseline scores of 14-24. Exclusion criteria: any psychoorganic disorder, drug abuse, a psychotic disorder, a dissociative disorder, serious communication problem, physical restrictions, being "too ill" and/or "too suicidal", pregnancy or a wish to become pregnant. Exclusion criteria associated with medication were: a contra-indication for one of the antidepressants prescribed by the pharmacotherapy protocol, a history of adequate treatment with antidepressants during the present depressive episode, and use of psychotropic medication not prescribed by the pharmacotherapy protocol. *Intervention*: Short psychodynamic supportive psychotherapy (SPSP). SPSP consists of up to 16 sessions delivered within a 6-month period. Comparators: Pharmacotherapy (Pharmacotherapy was provided in accordance with an antidepressant medication protocol, allowing for changes in medication in response to inefficacy or intolerance) and SPSP and pharmacotherapy combined. Treatment was intended to last for 6 months. Outcome: depressive symptoms (Hamilton Rating Scale for Depression; Clinical Global Impression of Severity and Improvement; the depression subscale of the 90psychotherapy = 97, combined = 171)

treatment. We have only extracted results for the last comparison as it is relevant to this BEST summary.

At 24 weeks, no significant differences in remission and response rates were found between combined therapy and short psychodynamic supportive psychotherapy, except for one outcome – the Symptom Checkist depression subscale (which favoured combined therapy, p=0.016).

Regarding mean scores, two of five outcomes were found to significantly differ between psychotherapy alone vs. combined treatment – the Symptom Checkist depression subscale (which favoured combined therapy, p=0.001), and the QLDS (which favoured combined therapy, p=0.031).

Symptom Checklist; Quality of Life		
Depression Scale).		

RCTs

Author	Inclusion criteria	Number of	Summary of results	Risk of bias
(year)		participants		
Blom	Participants: Aged 18 years and over with	N=193	After 12-16 weeks of treatment, all treatments were found to	Unclear
et al.	a DSM-IV diagnosis of major depressive		be effective, but there were no significant differences	
(2007)	disorder and a score of 14 or above on the		between treatment groups using the HAMD. In contrast, the	
	HRSD). Exclusion criteria: substance abuse,		combination of medication with psychotherapy was found to	
	a serious medical condition, organic		be more effective in reducing depressive symptoms (as	
	psychiatric disorder, severe suicidality,		measured using MADRS) compared to medication alone, but	
	history of psychotic disorder or		not to psychotherapy alone.	
	schizophrenia, bipolar disorder, current			
	use of psychotropic medication and			
	ongoing psychotherapy.			
	Intervention: 12 sessions of Interpersonal			
	Psychotherapy over a 16 week period,			
	delivered by trained IPT therapists.			
	Comparator: either (1) Nefazodone (100			
	mg per day initially and gradually			
	increased to 400 mg a day. If insufficient			
	improvement after 4 weeks, dose was			
	increased to 600 mg); or (2) IPT and			
	Nefazodone combined.			
	Outcome: Primary outcome: depressive			
	symptoms (HAMD). Secondary outcomes:			

	depressive symptoms (Montgomery-			
	Asberg Depression rating Scale) general			
	mental health symptomatology (Clinical			
	Global Impression Scale).			
Zu et	Participants: Aged between 17 and 60	N=180	After 6 months, there was no significant difference between	High
al.	with a diagnosis of non- psychotic DSM-IV		any of the treatment groups for HAMD, QIDS-R, or WSAS	
(2014)	major depressive disorder (length of illness		(statistical results for the various group comparisons are not	
	less than 1 year); a total score of the HRSD		clearly reported).	
	or 17 or above; ability to communicate;			
	have at least one family member			
	cohabiting with them. Exclusion criteria:			
	current or past history of any other			
	psychiatric disorders including drug and			
	alcoholic dependence; ongoing acute			
	medical and neurological conditions; lack			
	of response to citalopram, sertraline, or			
	paroxetine; having had CBT previously;			
	taking an antipsychotic medication or			
	mood stabilizer; suicidal ideation, suicide			
	plan or attempt in the current depressive			
	episode.			
	Intervention: 24- week individual CBT,			
	comprising 20 sessions each lasting 1 hour.			
	Session content included establishing a			
	therapeutic goal and plan, understanding			
	patterns of automatic thoughts and			
	behaviours, and identifying warning signs			
	of relapse.			
	Comparator: either (1) antidepressant			

medication (Citalopram (20–60 mg/day)		
escitalopram (10–20 mg/day), paroxetin	9	
(20–60 mg/day), orsertraline (25–		
100mg/day) within the therapeutic dose		
ranges recommended by the Guidelines		
for the Prevention and Treatment of Ma	or	
Depression in China); or (2) a combination	n	
of CBT and antidepressant medication.		
Outcome: depressive symptoms (HRSD;		
Quick Inventory of Depressive		
Symptomatology-Self Report); social		
functioning (Work and Social Adjustmen	:	
Scale).		

Risk of Bias:

SRs

Author (year)	Risk of Bias					
	Inclusion criteria	Searches	Review Process	Quality assessment	Synthesis	
Cuijpers et al. (2009)	©	©	?	©	(()	
Cuijpers et al. (2012)	©	©	©	©	©	

Mega-Analyses

Study		RISK OF BIAS							
	Random allocation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective Reporting			
De Maat (2008)	?	?	?	?	©	<u></u>			

RCTs

Study			RISK O	F BIAS		
	Random allocation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective Reporting
Blom et al. (2007)	?	?	Open label	©	©	©
Zu et al. (2014)	©	?	Open label	<u></u>	8	8





? Unclear Risk

Search Details

Source	Search Strategy	Number	Relevant
		of hits	evidence
			identified
· · ·			
NICE	cbt combined antidepressant depression	36	1
DARE	(depress*) IN DARE FROM 2006 TO 2014 1412 Delete	196	2
	2 MeSH DESCRIPTOR Depression EXPLODE ALL TREES 513 Delete		
	3 MeSH DESCRIPTOR Depressive Disorder EXPLODE ALL TREES 922 Delete		
	4 MeSH DESCRIPTOR Depressive Disorder, Major EXPLODE ALL TREES 292 Delete		
	5 #1 OR #2 OR #3 OR #4 2069 Delete		
	6 (psychotherap*) IN DARE FROM 2006 TO 2014 526 Delete		
	7 MeSH DESCRIPTOR Psychotherapy EXPLODE ALL TREES 1837 Delete		
	8 (therap*) IN DARE FROM 2006 TO 2014 13771 Delete		
	9 ((combined adj2 modalit*) OR combination*) IN DARE FROM 2006 TO 2014 3224		
	Delete		
	10 #6 OR #7 OR #8 14742 Delete		
	11 #9 AND #10 2408 Delete		
	12 #5 AND #11		
Primary st	tudies		
CENTRAL	#1 depression or depressive:ti 14397	490	2
	#2 mood or affective or adjustment:ti 3431		
	#3 MeSH descriptor: exp[Depression] 5420		
	#4 MeSH descriptor: exp[Depressive Disorder] 7497		
	#5 MeSH descriptor: [Mood Disorders] 442		
	#6 {or #1-#5}{or #1-#5} 23288		
	#7 psychotherapy or psychodynamic or psychoanal*psychotherapy or psychodynamic		
	or psychoanal* 8576 #8 MeSH descriptor: [Psychotherapy] 15658		
	#8 MeSH descriptor: [Psychotherapy] 15658		

	#9 DDBT or CBT or psychoeducation or formulation 16506		
	#10 (behavio* or cognitive or group) near/3 therap* 26929		
	#11 {or #7-#10}{or #7-#10} 48747		
	#12 MeSH descriptor: [Antidepressive Agents] 4896		
	#13 antidepressant* or tricyclic* or SSRI* or "mood stabli?er"9226		
	#14 "drug therapy" or pharmacotherapy218155		
	#15 Serotonin-Reuptake-Inhibitor*1897		
	#16 Serotonin-Re-uptake-Inhibitor*352		
	#17 Monoamine-oxidase-inhibitor*732		
	#18 {or #12-#17}222541		
	#19 #6 and #11 and #181647		
	#20 2006 or 2007 or 2008 or 2009 or 2010 or 2011 or 2012 or 2013 or 2014371482		
	#21 #19 and #201043		
	#22 child* or adolesc*152288		
	#23 #21 not #22 705 (490 in Central)		
PsycINFO	1. PsycINFO; (Depression OR Depressive).ti,ab; 200066 results.	241	
	2. PsycINFO; exp MAJOR DEPRESSION/; 93891 results.		
	3. PsycINFO; Mood-Disorder*.ti,ab; 10785 results.		
	4. PsycINFO; exp AFFECTIVE DISORDERS/; 120583 results.		
	5. PsycINFO; Affective-Disorder*.ti,ab; 14057 results.		
	6. PsycINFO; 1 OR 2 OR 3 OR 4 OR 5; 230438 results.		
	7. PsycINFO; Antidepressants.ti,ab; 15757 results.		
	8. PsycINFO; SSRI*.ti,ab; 4879 results.		
	9. PsycINFO; Tricyclic*.ti,ab; 5069 results.		
	10. PsycINFO; Mood-Stabili?er*.ti,ab; 2477 results.		
	11. PsycINFO; Serotonin-Reuptake-Inhibitor*.ti,ab; 6566 results.		
	12. PsycINFO; Serotonin-Re-uptake-Inhibitor*.ti,ab; 300 results.		
	13. PsycINFO; drug-therapy.ti,ab; 2854 results.		
	14. PsycINFO; DRUG THERAPY/; 108330 results.		
	15. PsycINFO; exp ANTIDEPRESSANT DRUGS/; 32062 results.		
	1 25 5 7 5 5 7 5 1113 21 11235 1111 2110 237 7 32302 1233131		

- 16. PsycINFO; exp SEROTONIN REUPTAKE INHIBITORS/; 10567 results.
- 17. PsycINFO; exp MONOAMINE OXIDASE INHIBITORS/; 2118 results.
- 18. PsycINFO; Monoamine-oxidase-inhibitor*.ti,ab; 946 results.
- 19. PSyCINFO; exp SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS/; 1314 results.
- 20. PsycINFO; 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR
- 19; 125961 results.
- 21. PsycINFO; Psychotherapy.ti,ab; 72333 results.
- 22. PsycINFO; exp PSYCHOTHERAPY/; 177009 results.
- 23. PsycINFO; exp COGNITIVE THERAPY/; 11683 results.
- 24. PsycINFO; exp GROUP PSYCHOTHERAPY/; 19771 results.
- 25. PsycINFO; (psychotherap* OR psychodynam* OR psychoanaly*).ti,ab; 154877 results.
- 26. PsycINFO; ((behavio* OR cognitive OR group) adj2 therap*).ti,ab; 41798 results.
- 27. PsycINFO; "transactional analy*".ti,ab; 1376 results.
- 28. PsycINFO; (solution* adj2 focus*).ti,ab; 1522 results.
- 29. PsycINFO; (DBT OR CBT).ti,ab; 8577 results.
- 30. PsycINFO; "schema therapy".ti,ab; 212 results.
- 31. PsycINFO; psychoeducation*.ti,ab; 6191 results.
- 32. PsycINFO; formulation.ti,ab; 13504 results.
- 33. PsycINFO; 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32; 275404 results.
- 34. PsycINFO; 6 AND 20 AND 33; 4207 results.
- 35. PsycINFO; CLINICAL TRIALS/; 7801 results.
- 36. PsycINFO; random*.ti,ab; 132312 results.
- 37. PsycINFO; groups*.ti,ab; 371690 results.
- 38. PsycINFO; (doubl* adj3 blind*).ti,ab; 18455 results.
- 39. PsycINFO; (singl* adj3 blind*).ti,ab; 1669 results.
- 40. PsycINFO; EXPERIMENTAL DESIGN/; 9233 results.
- 41. PsycINFO; controlled.ti,ab; 82103 results.
- 42. PsycINFO; (clinical adj3 study).ti,ab; 8049 results.

	43. PsycINFO; trial.ti,ab; 69577 results.		
	44. PsycINFO; "treatment outcome clinical trial".md; 27525 results.		
	45. PsycINFO; 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44; 575950		
	results.		
	46. PsycINFO; 34 AND 45; 1613 results.		
	47. PsycINFO; 46 [Limit to: Publication Year 2006-2014]; 829 results.		
	48. PsycINFO; 47 [Limit to: (Methodology 2000 Treatment Outcome/Clinical Trial) and		
	Publication Year 2006-2014]; 241 results.		
Embase	49. EMBASE; (Depression OR Depressive).ti,ab; 310929 results.	739	
	50. EMBASE; Mood-Disorder*.ti,ab; 15495 results.		
	51. EMBASE; Affective-Disorder*.ti,ab; 16547 results.		
	52. EMBASE; MOOD DISORDER/ OR MAJOR AFFECTIVE DISORDER/ OR exp DEPRESSION		
	[+NT]/; 323307 results.		
	53. EMBASE; 49 OR 50 OR 51 OR 52; 450738 results.		
	54. EMBASE; Antidepressants.ti,ab; 33823 results.		
	55. EMBASE; SSRI*.ti,ab; 11146 results.		
	56. EMBASE; Tricyclic*.ti,ab; 17275 results.		
	57. EMBASE; Mood-Stabili?er*.ti,ab; 4154 results.		
	58. EMBASE; Serotonin-Reuptake-Inhibitor*.ti,ab; 12628 results.		
	59. EMBASE; Serotonin-Re-uptake-Inhibitor*.ti,ab; 954 results.		
	60. EMBASE; drug-therapy.ti,ab; 36197 results.		
	61. EMBASE; Monoamine-oxidase-inhibitor*.ti,ab; 3525 results.		
	62. EMBASE; exp TRICYCLIC ANTIDEPRESSANT/; 91257 results.		
	63. EMBASE; exp ANTIDEPRESSANT AGENT/; 302406 results.		
	64. EMBASE; exp MOOD STABILIZER/; 5403 results.		
	65. EMBASE; 54 OR 55 OR 56 OR 57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64; 347078		
	results.		
	66. EMBASE; Psychotherapy.ti,ab; 34339 results.		
	67. EMBASE; (psychotherap* OR psychodynam* OR psychoanaly*).ti,ab; 61721 results.		

	68. EMBASE; ((behavio* OR cognitive OR group) adj2 therap*).ti,ab; 41973 results.		
	69. EMBASE; "transactional analy*".ti,ab; 235 results.		
	70. EMBASE; (solution* adj2 focus*).ti,ab; 623 results.		
	71. EMBASE; (DBT OR CBT).ti,ab; 9368 results.		
	72. EMBASE; "schema therapy".ti,ab; 108 results.		
	73. EMBASE; psychoeducation*.ti,ab; 3862 results.		
	74. EMBASE; formulation.ti,ab; 87102 results.		
	75. EMBASE; exp PSYCHOTHERAPY/; 181125 results.		
	76. EMBASE; 66 OR 67 OR 68 OR 69 OR 70 OR 71 OR 72 OR 73 OR 74 OR 75; 313050		
	results.		
	77. EMBASE; 53 AND 65 AND 76; 14646 results.		
	78. EMBASE; 77 [Limit to: (Clinical Queries Therapy maximizes specificity) and Publication		
	Year 2006-2014]; 727 results.		
	79. EMBASE; 77 [Limit to: (Clinical Trials Randomized Controlled Trial) and Publication Year		
	2006-2014]; 739 results.		
Medline	30. MEDLINE; (Depression OR Depressive).ti,ab; 252608 results.	463	
	31. MEDLINE; Mood-Disorder*.ti,ab; 11035 results.		
	32. MEDLINE; Affective-Disorder*.ti,ab; 13534 results.		
	33. MEDLINE; MOOD DISORDER/ OR MAJOR AFFECTIVE DISORDER/ OR exp DEPRESSION		
	[+NT]/; 88105 results.		
	34. MEDLINE; 30 OR 31 OR 32 OR 33; 292141 results.		
	35. MEDLINE; Antidepressants.ti,ab; 25238 results.		
	36. MEDLINE; SSRI*.ti,ab; 7147 results.		
	37. MEDLINE; Tricyclic*.ti,ab; 13649 results.		
	38. MEDLINE; Mood-Stabili?er*.ti,ab; 2648 results.		
	39. MEDLINE; Serotonin-Reuptake-Inhibitor*.ti,ab; 9798 results.		
	40. MEDLINE; Serotonin-Re-uptake-Inhibitor*.ti,ab; 748 results.		
	41. MEDLINE; drug-therapy.ti,ab; 28981 results.		
	42. MEDLINE; Monoamine-oxidase-inhibitor*.ti,ab; 3583 results.		
	46. MEDLINE; 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45; 72718		

	results. 47. MEDLINE; Psychotherapy.ti,ab; 25477 results.		
	48. MEDLINE; (psychotherap* OR psychodynam* OR psychoanaly*).ti,ab; 45563 results. 49. MEDLINE; ((behavio* OR cognitive OR group) adj2 therap*).ti,ab; 30699 results. 50. MEDLINE; "transactional analy*".ti,ab; 166 results.		
	51. MEDLINE; (solution* adj2 focus*).ti,ab; 462 results. 52. MEDLINE; (DBT OR CBT).ti,ab; 6555 results. 53. MEDLINE; "schema therapy".ti,ab; 66 results.		
	54. MEDLINE; psychoeducation*.ti,ab; 2667 results. 55. MEDLINE; formulation.ti,ab; 66209 results. 56. MEDLINE; exp PSYCHOTHERAPY/; 152488 results.		
	57. MEDLINE; 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56; 253527 results.		
	58. MEDLINE; exp ANTIDEPRESSIVE AGENTS/; 122615 results. 59. MEDLINE; 46 OR 58; 169269 results. 60. MEDLINE; 34 AND 57 AND 59; 4793 results.		
	61. MEDLINE; "randomized controlled trial".pt; 385578 results.62. MEDLINE; "controlled clinical trial".pt; 89643 results.		
	63. MEDLINE; 61 OR 62; 470295 results.64. MEDLINE; 60 AND 63; 867 results.65. MEDLINE; 64 [Limit to: Publication Year 2006-2014]; 463 results.		
Summary	NA	NA	

Disclaimer

BEST in MH answers to clinical questions are for information purposes only. BEST in MH does not make recommendations. Individual health care providers are responsible for assessing the applicability of BEST in MH answers to their clinical practice. BEST in MH is not responsible or liable for, directly or indirectly, any form of damage resulting from the use/misuse of information contained in or implied by these documents. Links to other sites are provided for information purposes only. BEST in MH cannot accept responsibility for the content of linked sites.

© Best Evidence Summaries of Topics in Mental Health 2013